MegaCMO Research · Published report preview

Daiken

Daiken Biomedical is a Taiwan supplement brand founded in 2018 by a pharmacist and listed under ticker 7780 on 9 September 2025, selling through its own store, eight third-party marketplaces, and physical chains including Watsons, Cosmed, FamilyMart, POYA, Matsumoto Kiyoshi, and several pharmacy groups. Its growth friction is not reach but the thinness of the first-party relationship behind that reach: the flagship fish oil shows a NT$1,980 list against a NT$1,320 promotional price, catalogue badges run from 75 percent of list all the way down to 28 percent of list, and a campaign line offering 16 percent off any single order above NT$8,400 stacks on top, which leaves the 20 percent monthly-subscription discount written into the terms with almost no commitment value. Changing or cancelling that subscription still requires calling the service center at least ten days before the next delivery, and no online self-serve control is visible on any public page. At the same time, the assets doing the most conversion work, from the specialist-recommended hero line to the doctor-recommendation and customer-testimonial sections of the feedback page and its free-product incentive for submitting a recommendation, land squarely on the formats the Ministry of Health and Welfare's Article 45 advertising principles name as aggravating factors, and they also sit under the labeling and advertising rules of Article 14 of the Health Food Control Act, so claim governance has to precede any spend increase. The single biggest opportunity is to convert the retail and marketplace buyers Daiken already pays distribution for into first-party subscribers through a pack-level replenishment entry point, because a replenishment-cycle promise is a service claim rather than a health-effect claim, can therefore scale safely inside Taiwan food-advertising limits, and is the one asset no marketplace or drugstore can take away.